Sorry, your browser is not compatible with this application. Please use the latest version of Google Chrome, Mozilla Firefox, Microsoft Edge or Safari.
China, Biotechnology, and BGI
As the U.S. government considers banning genomics companies from China, it opens a broader question about how the United States and other market economies should deal with China’s “national champions.”
This paper provides an overview of one such company—BGI—and how China’s industrial policy impacts technology development in China and around the world.
| Format: |
|
| Topics: | |
| Website: | Visit Publisher Website |
| Publisher: | Center for Security and Emerging Technology |
| Published: | May 1, 2024 |
| License: | Creative Commons |
| Copyright: | © 2024 by the Center for Security and Emerging Technology. This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0/. |
Featured Content
Contact Publisher
Claim Content